China’s NMPA Releases Draft Guidelines for Development Risk Management Plan
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released the...
May 2025
AstraZeneca’s Calquence Gains EU Approval for Mantle Cell Lymphoma
UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) announced receiving another indication approval in the European...
Huadong Medicine’s HDM2005 Receives NMPA Approval for DLBCL Clinical Trial
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...
Fresenius Medical Care Reports 1% Revenue Growth in Q1 2025
Germany-based Fresenius Medical Care (FRA: FMEA) released its 2025 Q1 financial report, showing total revenues...
Innovent Biologics Completes First Dosing in Phase II Study for Efdamrofusp Alfa in DME
China-based Innovent Biologics, Inc. (HKG: 1801) announced the completion of the first patient dosing in...
EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology
EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series...
Beijing Wantai’s HIV Urine Self-Test Kit Gains WHO Prequalification
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced that its HIV urine...
Formosa Pharmaceuticals Licenses Clobetasol Propionate to Apotex for Mexico
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with Apotex Inc., granting the...
Shuangcheng Pharma’s Generic Bivalirudin Approved by Australia’s TGA
China-based Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) announced that the market filing for its...
Everest Medicines’ Nefecon Receives Full Approval from NMPA for IgAN Treatment
China-based Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has converted...
Novartis to Acquire Regulus Therapeutics for Up to $1.7 Billion
Swiss pharmaceutical giant Novartis (NYSE: NVS) is set to acquire U.S.-based Regulus Therapeutics Inc. (NASDAQ:...
CSPC’s JMT202 Receives FDA IND Approval for Hypertriglyceridemia Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has secured an investigational new drug (IND) approval...
Guilin Sanjin’s BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials
Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275) announced that its Shanghai-based subsidiary Dragon Boat Biopharmaceutical’s...
Innovent Biologics Presents Positive IBI302 Results for nAMD at ARVO 2025
China-based Innovent Biologics, Inc. (HKG: 1801) announced the presentation of 1-year results from its Phase...
AccurEdit Therapeutics’ ART001 Shows Promising Results in ATTR Treatment
China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd. has published the latest data...
Novo Nordisk’s Once-Daily Wegovy NDA Accepted for FDA Review
Denmark-based Novo Nordisk (NYSE: NVO) announced that its New Drug Application (NDA) filing for its...
Nanjing Perlove Medical Equipment Files IPO Application in Hong Kong
China-based Nanjing Perlove Medical Equipment Co., Ltd., a specialist in medical imaging and surgical robotics,...
Sanofi’s Opella Becomes Independent Consumer Healthcare Company After CD&R Deal
Opella, the consumer health business of French pharmaceutical giant Sanofi (NASDAQ: SNY), became an independent...
Johnson & Johnson’s Imaavy Gains FDA Approval for Generalized Myasthenia Gravis
US giant Johnson & Johnson (J&J, NYSE: JNJ) unveiled a market approval in the United...
Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial
China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene...